These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
199 related articles for article (PubMed ID: 30588904)
41. Pimavanserin for the treatment of Parkinson's disease psychosis: number needed to treat, number needed to harm, and likelihood to be helped or harmed. Citrome L; Norton JC; Chi-Burris K; Demos G CNS Spectr; 2018 Jun; 23(3):228-238. PubMed ID: 29098976 [TBL] [Abstract][Full Text] [Related]
42. Second-generation antipsychotics for Parkinson's disease psychosis: A systematic review and network meta-analysis. Srisurapanont M; Suradom C; Suttajit S; Kongsaengdao S; Maneeton B Gen Hosp Psychiatry; 2024; 87():124-133. PubMed ID: 38412585 [TBL] [Abstract][Full Text] [Related]
43. Mortality in Patients with Parkinson's Disease-Related Psychosis Treated with Pimavanserin Compared with Other Atypical Antipsychotics: A Cohort Study. Layton JB; Forns J; McQuay LJ; Danysh HE; Dempsey C; Anthony MS; Turner ME Drug Saf; 2023 Feb; 46(2):195-208. PubMed ID: 36517664 [TBL] [Abstract][Full Text] [Related]
52. Pimavanserin use in a movement disorders clinic: a single-center experience. Mahajan A; Bulica B; Ahmad A; Kaminski P; LeWitt P; Taylor D; Krstevska S; Patel N Neurol Sci; 2018 Oct; 39(10):1767-1771. PubMed ID: 30032332 [TBL] [Abstract][Full Text] [Related]
53. Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer's disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study. Ballard C; Banister C; Khan Z; Cummings J; Demos G; Coate B; Youakim JM; Owen R; Stankovic S; Lancet Neurol; 2018 Mar; 17(3):213-222. PubMed ID: 29452684 [TBL] [Abstract][Full Text] [Related]
54. Psychosis in Parkinson Disease: A Review of Etiology, Phenomenology, and Management. Samudra N; Patel N; Womack KB; Khemani P; Chitnis S Drugs Aging; 2016 Dec; 33(12):855-863. PubMed ID: 27830568 [TBL] [Abstract][Full Text] [Related]
55. Pimavanserin: First Global Approval. Markham A Drugs; 2016 Jul; 76(10):1053-7. PubMed ID: 27262680 [TBL] [Abstract][Full Text] [Related]
56. Management of Parkinson's Disease Psychosis. Elsibai H; Kualleny M; Fandy TE Sr Care Pharm; 2022 Aug; 37(8):339-344. PubMed ID: 35879841 [No Abstract] [Full Text] [Related]
57. Retrospective analyses evaluating the mortality risk associated with pimavanserin or other atypical antipsychotics in patients with Parkinson disease psychosis. Isaacson SH; Pahwa R; Pagan F; Abler V; Truong D Clin Park Relat Disord; 2024; 10():100256. PubMed ID: 38770047 [TBL] [Abstract][Full Text] [Related]
58. Nighttime Sleep and Daytime Sleepiness Improved With Pimavanserin During Treatment of Parkinson's Disease Psychosis. Patel N; LeWitt P; Neikrug AB; Kesslak P; Coate B; Ancoli-Israel S Clin Neuropharmacol; 2018; 41(6):210-215. PubMed ID: 30303817 [TBL] [Abstract][Full Text] [Related]
59. Evaluating pimavanserin as a treatment for psychiatric disorders: A pharmacological property in search of an indication. Davis J; Zamora D; Horowitz M; Leucht S Expert Opin Pharmacother; 2021 Sep; 22(13):1651-1660. PubMed ID: 34404290 [No Abstract] [Full Text] [Related]
60. Pimavanserin, a 5-HT2A inverse agonist, reverses psychosis-like behaviors in a rodent model of Parkinson's disease. McFarland K; Price DL; Bonhaus DW Behav Pharmacol; 2011 Oct; 22(7):681-92. PubMed ID: 21921840 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]